Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation

Area of Science:

• Oncology
• Cell Biology
• Cancer Stem Cell Research

Background:

• Cancer stem cells (CSCs) are key drivers of tumor growth and therapeutic resistance.
• Oct4 is a transcription factor found in CSC-like cells, but its role in tumor cells is not fully understood.

Purpose of the Study:

• To investigate the function of Oct4 in promoting dedifferentiation of melanoma cells towards a CSC phenotype.
• To elucidate the mechanisms underlying Oct4-mediated dedifferentiation and its impact on tumor progression.

Main Methods:

• Manipulating Oct4 gene expression and protein delivery in melanoma cells.
• Assessing phenotypic changes, including marker expression, spheroid formation, and drug/hypoxia resistance.
• Evaluating tumorigenic capacity using xenograft and tail vein injection models.
• Analyzing gene expression changes and the role of Oct4 knockdown.

Main Results:

• Oct4 expression or protein delivery induced melanoma cell dedifferentiation into CSC-like cells.
• Dedifferentiated cells showed reduced melanocytic markers, increased resistance to chemotherapy and hypoxia, and enhanced tumorigenicity.
• Oct4-induced dedifferentiation involved upregulation of stemness genes (Oct4, Nanog, Klf4) and global transcriptional changes.
• Knockdown of Oct4 reversed CSC phenotypes, and Oct4 expression was linked to hypoxia in clinical melanoma samples.

Conclusions:

• Oct4 acts as a positive regulator of tumor cell dedifferentiation, enabling the acquisition of CSC phenotypes.
• The CSC phenotype is dynamic and can be acquired through Oct4-mediated dedifferentiation.
• Oct4-driven dedifferentiation may play a significant role in melanoma progression and therapeutic resistance.